A phase 3, randomized, double-blind study of pembrolizumab plus ipilimumab vs pembrolizumab plus placebo in previously untreated, stage IV, metastatic non-small cell lung cancer subjects whose tumors are PD-L1 positive (TPS ≥ 50%) (KEYNOTE-598). NCT03302234
A phase III, randomized, multi-center, open-label, comparative global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for first-line treatment in patients with metastatic non small-cell lung cancer (NSCLC) (POSEIDON). NCT03164616
A phase III, open-label, randomized study of atezolizumab (MPDL3280A, anti-PD-L1 antibody) in combination with carboplatin + paclitaxel with or without bevacizumab compared with carboplatin + paclitaxel + bevacizumab in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer. NCT02366143
Banna G et al. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: Primum non nocere. ESMO Open 2020 Apr;5(2). pii: e000765. Abstract
Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015;3377-83. Abstract
Camidge DR et al. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol 2019;16(6):341-55. Abstract
Cavanna L et al. Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. Oncotarget 2019;10(2):209-15. Abstract
Hellmann MD et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019;381(21):2020-31. Abstract
Mazieres J et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry. Ann Oncol 2019;30(8):1321-8. Abstract
Peters S et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis. ESMO 2019;Abstract LBA4_PR.
Ramalingam SS et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. ASCO 2020;Abstract 9500.
Reck M et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. ASCO 2020;Abstract 9501.
Rodriguez-Abreu D et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). ASCO 2020;Abstract 9503.
West H et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20(7):924-37. Abstract